Cell therapies articles within Nature Reviews Clinical Oncology

Featured

  • Comment |

    In 2017, FDA Oncology approved 17 new drug and biologic applications, 32 supplemental drug and biologic applications, and two biosimilar applications in oncology. These actions included landmark approvals of two chimeric antigen receptor T cell therapies and the first site-agnostic, biomarker-defined approval. Three next-generation sequencing 'oncopanels' designed to detect hundreds of somatic genetic aberrations were also approved.

    • Gideon M. Blumenthal
    •  & Richard Pazdur

  • Review Article |

    Cell-based immunotherapies are showing great promise in the treatment of even the most treatment-refractory of haematological malignancies. Herein, Jennifer Brudno and James Kochenderfer review the results obtained to date with CAR-T-cell therapies for lymphoma. They also discuss what has been learned regarding the limitations of CAR-T-cell therapies and areas for improvement relating to toxicity management, the design of CAR-T-cell products, conditioning regimens, and combination therapies.

    • Jennifer N. Brudno
    •  & James N. Kochenderfer

  • Review Article |

    Clinical trials of CAR-T-cell therapy for patients with B-cell malignancies have yielded impressive results. Ongoing clinical trials are now testing CAR-T-cell therapies with new designs for the treatment of other haematological and solid malignancies. The authors of this Review present an overview of the approaches that are currently being tested in registered clinical trials, and discuss strategies that can increase the antitumour efficacy and safety of CAR-T-cell therapy.

    • Hollie J. Jackson
    • , Sarwish Rafiq
    •  & Renier J. Brentjens

  • Review Article |

    The aim of immunotherapy is to treat cancer by enabling the immune system to attack the tumour. In the past decade, remarkable results have been obtained in clinical trials with immunotherapy for patients with advanced-stage cancer. Two types of immunotherapy have been used in the majority of trials conducted in the past decade: immune cell-targeted antibody therapy and adoptive cellular therapy. Herein, the latest advances in both modalities are discussed, including settings for which testing combination strategies and 'armoured' CAR T cells are recommended.

    • Danny N. Khalil
    • , Eric L. Smith
    •  & Jedd D. Wolchok

  • Review Article |

    This Review describes current strategies and future approaches to improve T cell-based therapies to treat post-transplant lymphoproliferative disease, a serious and often life-threatening complication that is associated with Epstein-Barr virus and can occur after haematopoietic stem-cell or solid organ transplantation.

    • Catherine M. Bollard
    • , Cliona M. Rooney
    •  & Helen E. Heslop

  • Review Article |

    The ability to follow the distribution and migration of biologically active cells in living organisms is crucial for the development of cell-based therapies. In this Review, Kircher et al. describe the imaging principles underlying currently available cell-tracking methods and highlight recent examples of their application in animal models and patients.

    • Moritz F. Kircher
    • , Sanjiv S. Gambhir
    •  & Jan Grimm

Browse broader subjects

Browse narrower subjects

Browse Cell therapies across other nature.com journals